NICE publishes febuxostat guidance after appeal fails
This article was originally published in Scrip
Executive Summary
The UK's National Institute for health and Clinical Excellencehas published guidance on the use ofIpsen's Adenuric (febuxostat, licensed from Teijin Pharma) for the treatment of chronic hyperuricaemia in gout after dismissing the company's appeal against a draft appraisal (Scrip Online, August 19th, 2008).